Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-08-23 Delisting Announcement
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia ADSs delisted from NASDAQ in the US
Delisting Announcement Classification · 100% confidence The document explicitly announces that Oasmia Pharmaceutical AB has completed the delisting of its American Depositary Shares (ADS) from the Nasdaq Capital Market. It explains the purpose of the delisting and provides instructions for ADS holders. Since the document is a formal announcement regarding the removal of securities from an exchange, it fits the definition of a Delisting Announcement.
2019-08-23 English
Oasmia ADSs delisted from NASDAQ in the US
Delisting Announcement Classification · 100% confidence The document explicitly announces that Oasmia Pharmaceutical AB has completed the delisting of its American Depositary Shares (ADS) from the Nasdaq Capital Market. It explains the purpose of the delisting and provides instructions for ADS holders. Since the document is a formal announcement regarding the removal of securities from an exchange, it fits the definition of a Delisting Announcement.
2019-08-23 English
Oasmias depåbevis avnoterade från NASDAQ i USA
Delisting Announcement Classification · 100% confidence The document is a short announcement (under 2,500 characters) from Oasmia Pharmaceutical AB confirming that the delisting of its American Depositary Shares (ADS) from the Nasdaq Capital Market has been completed. While the subject matter is a delisting, the document serves as a formal notification to the public and shareholders regarding this corporate action. According to the 'Menu vs Meal' rule, this is an announcement of a corporate event rather than a complex legal filing, and it fits the definition of a delisting announcement.
2019-08-23 Swedish
Oasmia ADSs delisted from NASDAQ in the US
Delisting Announcement Classification · 100% confidence The document explicitly announces that Oasmia Pharmaceutical AB has completed the delisting of its American Depositary Shares (ADS) from the Nasdaq Capital Market. It explains the purpose of the delisting and provides instructions for ADS holders. Since the document is a formal announcement regarding the removal of securities from an exchange, it fits the definition of a Delisting Announcement.
2019-08-23 English
Oasmias depåbevis avnoterade från NASDAQ i USA
Delisting Announcement Classification · 98% confidence The document text, written primarily in Swedish, announces that Oasmia Pharmaceutical AB has completed the delisting (avnotering) of its American Depositary Receipts (ADS) from the Nasdaq Capital Market in the USA. It explains the purpose (reducing reporting complexity and administrative costs) and details the transition to the OTC market and the option for investors to redeem ADS for common shares trading on Nasdaq Stockholm. The key event described is the cessation of trading on a specific exchange, which directly corresponds to a delisting announcement. The presence of an attached file named 'PM avlistning ADS 23 aug FINAL' (Press Release delisting ADS 23 Aug FINAL) confirms this focus. This aligns perfectly with the definition for Delisting Announcement (DLST).
2019-08-23 Swedish
Oasmias depåbevis avnoterade från NASDAQ i USA
Delisting Announcement Classification · 99% confidence The document is a press release dated August 23, 2019, with the headline 'Oasmias depåbevis avnoterade från NASDAQ i USA' (Oasmia's American Depositary Receipts delisted from NASDAQ in the USA). The text explicitly states that the delisting has been completed and explains the rationale (reducing reporting complexity and administrative costs). This directly concerns the removal of the company's stock from a major exchange. This aligns perfectly with the definition for Delisting Announcement (DLST). The document is short and is an announcement, not a comprehensive financial report.
2019-08-23 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.